Pirfenidone and Its Role in Burn Wound Healing

• Status: Completed
• Trial end date: 2017-06-22
• Target enrollment: 0
• Participant gender: All

Summary

Burn patients which skin has been lost a rapid growth of the skin is a foremost in their treatment. Due to the injury, burn patients undergo a systemic inflammation that helps the skin heal faster. However, several studies have shown that this inflammation increases the levels of several inflammatory molecules that impairs skin growing, which further delays the recovery of burn patients. As such, by inhibiting these inflammatory molecules with the administration of a medication called pirfenidone burn patients might present faster rates of skin growth and recovery. Thus, patients suffering from a burn injury will be recruited at the emergency department of the Hospital University in Monterrey Mexico. Afterward, patients will be randomized to either receive pirfenidone 600 mg orally once per day or usual care consisting of covering the wound with hydrocolloid dressings. To assess the amount of newly growth skin investigators will take a small piece of the skin to further evaluate it through a microscope.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universidad Autonoma de Nuevo Leon
• Treatments: Pirfenidone

Criteria

Inclusion Criteria:

• Patients with second-degree burns from any etiology with less than 24 hours of evolution.

Exclusion Criteria:

• Patients <18 years old

• Patients allergic to pirfenidone

• Pregnant patients

• Patients with renal or hepatic failure

• Patients who are not able to take the medication orally

• Conditions or drugs that alter wound healing (i.e. any kind of diabetes, lupus, having a history of using steroids, rheumatoid arthritis)